CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.

ABSTRACT:

Background

Tamoxifen treatment greatly reduces a woman's risk of developing a second primary breast cancer. There is, however, substantial variability in treatment response, some of which may be attributed to germline genetic variation. CYP2D6 is a key enzyme in the metabolism of tamoxifen to its active metabolites, and variants in this gene have been associated with reduced tamoxifen metabolism. The impact of variation on risk of contralateral breast cancer (CBC) is unknown.

Methods

Germline DNA from 1514 CBC cases and 2203 unilateral breast cancer controls was genotyped for seven single nucleotide polymorphisms, one three-nucleotide insertion-deletion, and a full gene deletion. Each variant has an expected impact on enzyme activity, which in combination allows for the clas

SUBMITTER: Brooks JD 

PROVIDER: S-EPMC6288916 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature